1.
Kevin Young: Gilead
Kevin Young joined Gilead Sciences in 2004 as Executive Vice President of ... England and has completed the Executive Program at the University of Michigan. ...
2.
In less than one year,Gilead brought to market two novel ...
File Format: PDF/Adobe Acrobat - View as HTML belongs to a novel class of nucleotide analogue therapeutics. Pioneered by Gilead, this class of drugs is designed for selective and potent antiviral ...
3.
Products: Gilead
Learn more about Gilead's marketed products in the Gilead Corporate Overview. .... Truvada is not approved for the treatment of chronic hepatitis B virus ...
4.
Gilead 2006 Annual Report
Viral infections caused by hepatitis B and C are growing in prevalence worldwide ... GSK markets Hepsera in all countries outside of the Gilead territories, ...
5.
Gilead Sciences, Inc.
A biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for viral diseases, infectious diseases and cancer. Show stock quote for GILD
6.
Press Releases: Gilead
Gilead Sciences Inc. (Nasdaq: GILD) today announced that board member Donald H. Rumsfeld will assume the position of Chairman, effective immediately. ...
7.
Press Releases: Gilead
Gilead granted the initial purchasers an option to purchase an additional $50 million of the 2011 notes and $50 million of the 2013 notes to cover ...
8.
Microsoft PowerPoint - FINAL 08.01.07 JPMorgan Presentation with ...
File Format: PDF/Adobe Acrobat - View as HTML of 2007 and its subsequent current reports on Form 8-K. Gilead claims the ... statements are based on information currently available to Gilead, and ...
9.
Careers: Gilead
At Gilead, we are dedicated to advancing the care of patients suffering from ... in exploring the biotech industry and a career at Gilead Sciences. ...
10.
Press Releases: Gilead
Viread is now also indicated for the treatment of chronic hepatitis B in adults ... "The approval of Viread for hepatitis B represents more than a decade of ...
